Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes.
about
Targeting TGF-β Mediated SMAD Signaling for the Prevention of Fibrosis.Unfounded Claims of Improved Functional Outcomes Attributed to Follistatin Gene Therapy in Inclusion Body Myositis.Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches.Diabetes-induced hyperglycemia impairs male reproductive function: a systematic review.Endoplasmic Reticulum Stress Induces Myostatin High Molecular Weight Aggregates and Impairs Mature Myostatin Secretion.
P2860
Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Follistatin Gene Therapy for S ...... Improves Functional Outcomes.
@en
type
label
Follistatin Gene Therapy for S ...... Improves Functional Outcomes.
@en
prefLabel
Follistatin Gene Therapy for S ...... Improves Functional Outcomes.
@en
P2093
P2860
P1433
P1476
Follistatin Gene Therapy for S ...... Improves Functional Outcomes.
@en
P2093
Brian K Kaspar
Choumpree Curry
Igor Dvorchik
Jerry R Mendell
Katherine Berry
Kathleen Church
Kevin M Flanigan
Kim Shontz
Lindsay N Alfano
Louise R Rodino-Klapac
P2860
P304
P356
10.1016/J.YMTHE.2017.02.015
P50
P577
2017-03-06T00:00:00Z